About this document

CD24-Siglec-10: Target for Cancer Immunotherapy by leonardianh.195 is a document available to read on EtoBox.

The study identifies CD24 as a significant immune checkpoint in ovarian and triple-negative breast cancers, highlighting its role in immune evasion through interaction with macrophage Siglec-10. Monoclonal antibodies that block the CD24-Siglec-10 interaction enhance phagocytosis of cancer cells, suggesting therapeutic potential for CD24 blockade in cancer immunotherapy. The findings indicate that targeting CD24 could improve treatment outcomes for patients with these aggressive cancers.

Author

leonardianh.195

Language

EN